Infectivity and vaccination efficacy studies in animal models of HBV S and pol gene mutants

Antiviral Therapy

Volumn 15, Issue 3 PART B, 2010, Pages 477-485

  Kamili, Saleem ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

AMINO ACID SUBSTITUTION; CHIMPANZEE; DISEASE MODEL; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURAL GENE; VACCINATION; VIREMIA; VIRUS INFECTIVITY; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; WILD TYPE; ANIMAL; GENETICS; IMMUNOLOGY; MOUSE; MUTATION; PAN TROGLODYTES; PATHOGENICITY; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; GENES, POL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; MICE; MUTATION; PAN TROGLODYTES; TREATMENT OUTCOME; VACCINATION;

EID: 77953419649     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1520     Document Type: Review

References (98)

1. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49 Suppl 5:S174-S184.
2. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137:1593-1608.
3. Tabor E. Infections by hepatitis B surface antigen gene mutants in Europe and North America. J Med Virol 2006; 78 Suppl 1:S43-S47. (Pubitemid 43993464)
4. Trautwein C. Mechanisms of hepatitis B virus graft reinfection and graft damage after liver transplantation. J Hepatol 2004; 41:362-369. (Pubitemid 39158744)
5. Michitaka K, Akbar F, Onji M. Prevention of hepatitis B virus infection by vaccination: progress and problems. Hepatol Res 2007; 37:673-675. (Pubitemid 47054773)
6. Nainan OV, Khristova ML, Byun K, et al. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 2002; 68:319-327.
7. Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006; 78 Suppl 1:S52-S55. (Pubitemid 43993466)
8. Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008; 61:766-768. (Pubitemid 351426057)
9. Sloan RD, Ijaz S, Moore PL, Harrison TJ, Teo CG, Tedder RS. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 2008; 13:439-447. (Pubitemid 352016737)
10. Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002; 293:305-313.
11. Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002; 16:131-133. (Pubitemid 34062194)
12. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005; 25 Suppl 1:9-19. (Pubitemid 41254589)
13. Fortuin M, Karthigesu V, Allison L, et al. Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis 1994; 169:1374-1376. (Pubitemid 24164609)
14. Pichoud C, Seigneres B, Wang Z, Trepo C, Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 1999; 29:230-237. (Pubitemid 29024007)
15. Mutimer D, Pillay D, Cook P, et al. Selection of multiresistant hepatitis B virus during sequential nucleosideanalogue therapy. J Infect Dis 2000; 181:713-716. (Pubitemid 30131844)
16. Besisik F, Karaca C, Akyuz F, et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol 2003; 38:506-510. (Pubitemid 36399255)
17. Bowden S, Bartholomeusz A, Locarnini S. Lamivudine resistant occult HBV: implications for public health? J Hepatol 2003; 38:526-528. (Pubitemid 36399259)
18. Zanetti AR, Tanzi E, Manzillo G, et al. Hepatitis B variant in Europe. Lancet 1988; 332:1132-1133.
19. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccineinduced escape mutant of hepatitis B virus. Lancet 1990; 336:325-329. (Pubitemid 20264145)
20. Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 1997; 26:786-791.
21. Zuckerman JN, Zuckerman AJ. Mutations of the surface protein of hepatitis B virus. Antiviral Res 2003; 60:75-78. (Pubitemid 37452449)
22. Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 1999; 30:1312-1317.
23. Datta S, Panigrahi R, Biswas A, et al. Genetic characterization of hepatitis B virus in peripheral blood leukocytes: evidence for selection and compartmentalization of viral variants with the immune escape G145R mutation. J Virol 2009; 83:9983-9992.
24. Locarnini S. Hepatitis B viral resistance: mechanisms and diagnosis. J Hepatol 2003; 39 Suppl 1:S124-S132. (Pubitemid 37222659)
25. Oon CJ, Chen WN, Goo KS, Goh KT. Intra-familial evidence of horizontal transmission of hepatitis B virus surface antigen mutant G145R. J Infect 2000; 41:260-264.
26. Chakravarty R, Neogi M, Roychowdhury S, Panda CK. Presence of hepatitis B surface antigen mutant G145R DNA in the peripheral blood leukocytes of the family members of an asymptomatic carrier and evidence of its horizontal transmission. Virus Res 2002; 90:133-141. (Pubitemid 35375830)
27. Yamamoto K, Horikita M, Tsuda F, et al. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 1994; 68:2671-2676. (Pubitemid 24091946)
28. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997; 4 Suppl 1:11-20.
29. Wallace LA, Echevarria JE, Echevarria JM, Carman WF. Molecular characterization of envelope antigenic variants of hepatitis B virus from Spain. J Infect Dis 1994; 170:1300-1303. (Pubitemid 24328642)
30. Swenson PD, Escobar MR, Carithers RL, Jr., Sobieski TJ, III. Failure of preexisting antibody against hepatitis B surface antigen to prevent subsequent hepatitis B infection. J Clin Microbiol 1983; 18:305-309.
31. Wands JR, Fujita YK, Isselbacher KJ, et al. Identification and transmission of hepatitis B virus-related variants. Proc Natl Acad Sci U S A 1986; 83:6608-6612.
32. Coursaget P, Yvonnet B, Bourdil C, et al. HBsAG positive reactivity in man not due to hepatitis B virus. Lancet 1987; 330:1354-1358. (Pubitemid 18007237)
33. Karthigesu VD, Allison LM, Fortuin M, Mendy M, Whittle HC, Howard CR. A novel hepatitis B virus variant in the sera of immunized children. J Gen Virol 1994; 75:443-448. (Pubitemid 24050406)
34. Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995; 345:1406-1407.
35. Carman WF, Trautwein C, van Deursen FJ, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24:489-493. (Pubitemid 26295985)
36. Waters JA, Kennedy M, Voet P, et al. Loss of the common 'a' determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest 1992; 90:2543-2547. (Pubitemid 23010076)
37. Oon CJ, Lim GK, Ye Z, et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 1995; 13:699-702.
38. Linnemann CC, Askey PA. Susceptibility to hepatitis B despite high titre anti-HBs antibody. Lancet 1984; 323:346-347.
39. Seddigh-Tonekaboni S, Waters JA, Jeffers S, et al. Effect of variation in the common 'a' determinant on the antigenicity of hepatitis B surface antigen. J Med Virol 2000; 60:113-121.
40. Kajiwara E, Tanaka Y, Ohashi T, et al. Hepatitis B caused by a hepatitis B surface antigen escape mutant. J Gastroenterol 2008; 43:243-247. (Pubitemid 351486687)
41. Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27:254-263. (Pubitemid 28041562)
42. Rodriguez-Frias F, Buti M, Jardi R, et al. Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation. Liver 1999; 19:177-182. (Pubitemid 29261582)
43. Ijaz S, Torre F, Tedder RS, Williams R, Naoumov NV. Novel immunoassay for the detection of hepatitis B surface 'escape' mutants and its application in liver transplant recipients. J Med Virol 2001; 63:210-216.
44. Kalinina T, Riu A, Fischer L, Will H, Sterneck M. A dominant hepatitis B virus population defective in virus secretion because of several S gene mutations from a patient with fulminant hepatitis. Hepatology 2001; 34:385-394. (Pubitemid 32702352)
45. Koyanagi T, Nakamuta M, Sakai H, et al. Analysis of HBs antigen negative variant of hepatitis B virus: unique substitutions, Glu129 to Asp and Gly145 to Ala in the surface antigen gene. Med Sci Monit 2000; 6:1165-1169. (Pubitemid 32009578)
46. Grethe S, Monazahian M, Bohme I, Thomssen R. Characterization of unusual escape variants of hepatitis B virus isolated from a hepatitis B surface antigen-negative subject. J Virol 1998; 72:7692-7696. (Pubitemid 28377913)
47. Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102:1930. (Pubitemid 37022596)
48. Alexopoulou A, Dourakis SP, Pandelidaki H, Archimandritis AJ, Karayiannis P. Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine. J Med Virol 2006; 78:1043-1046.
49. Alexopoulou A, Baltayiannis G, Jammeh S, Waters J, Dourakis SP, Karayiannis P. Hepatitis B surface antigen variant with multiple mutations in the a determinant in an agammaglobulinemic patient. J Clin Microbiol 2004; 42:2861-2865. (Pubitemid 38747561)
50. Awerkiew S, Daumer M, Reiser M, et al. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 2007; 38:83-86. (Pubitemid 44881426)
51. Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27:213-222. (Pubitemid 28041557)
52. Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122:264-273. (Pubitemid 34116979)
53. Torresi J, Earnest-Silveira L, Civitico G, et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the 'fingers' subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002; 299:88-99.
54. Jammeh S, Thomas HC, Karayiannis P. Replicative competence of the T131I, K141E, and G145R surface variants of hepatitis B Virus. J Infect Dis 2007; 196:1010-1013. (Pubitemid 47580294)
55. Kalinina T, Iwanski A, Will H, Sterneck M. Deficiency in virion secretion and decreased stability of the hepatitis B virus immune escape mutant G145R. Hepatology 2003; 38:1274-1281. (Pubitemid 37314837)
56. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol 2005; 32:102-112. (Pubitemid 40093960)
57. Tian Y, Xu Y, Zhang Z, et al. The amino acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen. J Clin Microbiol 2007; 45:2971-2978. (Pubitemid 47417342)
58. Ogata N, Zanetti AR, Yu M, Miller RH, Purcell RH. Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant. J Infect Dis 1997; 175:511-523. (Pubitemid 27086153)
59. Shizuma T, Hasegawa K, Ishikawa K, et al. Molecular analysis of antigenicity and immunogenicity of a vaccine-induced escape mutant of hepatitis B virus. J Gastroenterol 2003; 38:244-253. (Pubitemid 36527127)
60. Kamili S, Sozzi V, Thompson G, et al. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 2009; 49:1483-1491.
61. Ogata N, Cote PJ, Zanetti AR, et al. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology 1999; 30:779-786. (Pubitemid 29409424)
62. Chotiyaputta W, Lok AS. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009; 6:453-462.
63. Sheldon J, Rodes B, Zoulim F, Bartholomeusz A, Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 2006; 13:427-434. (Pubitemid 43911751)
64. Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107:449-455.
65. Delaney WE, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77:11833-11841.
66. Seigneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002; 36:710-722.
67. Fu L, Cheng YC. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in l(-)SddC (3TC) resistance. Biochem Pharmacol 1998; 55:1567-1572.
68. Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33:751-757.
69. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628-633.
70. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 1999; 59:270-276.
71. Cooley L, Ayres A, Bartholomeusz A, et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV - HBV co-infected individuals. AIDS 2003; 17:1649-1657.
72. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002; 25:97-106.
73. Sheldon J, Ramos B, Garcia-Samaniego J, et al. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr 2007; 46:279-282.
74. Wakil SM, Kazim SN, Khan LA, et al. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus. J Med Virol 2002; 68:311-318.
75. Ohishi W, Shirakawa H, Kawakami Y, et al. Identification of rare polymerase variants of hepatitis B virus using a twostage PCR with peptide nucleic acid clamping. J Med Virol 2004; 72:558-565.
76. Xiong X, Yang H, Westland CE, Zou R, Gibbs CS. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 2000; 31:219-224.
77. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31:1318-1326.
78. Tillmann HL, Trautwein C, Bock T, et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIG immunoglobulin after liver transplantation. Hepatology 1999; 30:244-256.
79. Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV - HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20:863-870.
80. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131:1253-1261.
81. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129-134.
82. Angus P, Locarnini S. Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off! Antivir Ther 2004; 9:145-148.
83. Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39:1085-1089.
84. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292-297.
85. Yang H, Westland CE, Delaney WE, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36:464-473.
86. Seigneres B, Pichoud C, Ahmed SS, Hantz O, Trepo C, Zoulim F. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. J Infect Dis 2000; 181:1221-1233.
87. Schildgen O, Schewe CK, Vogel M, et al. Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS 2004; 18:2325-2327.
88. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48:3498-3507.
89. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49:1503-1514.
90. Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16:2352-2354.
91. Nunez M, Puoti M, Camino N, Soriano V. Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. Clin Infect Dis 2003; 37:1678-1685.
92. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapynaive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189:1185-1192.
93. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9:353-363.
94. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med 1982; 307:1481-1486.
95. Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003; 63:1021-1051.
96. Weber B, Melchior W, Gehrke R, Doerr HW, Berger A, Rabenau H. Hepatitis B virus markers in anti-HBc only positive individuals. J Med Virol 2001; 64:312-319.
97. Berger A, Doerr HW, Rabenau HF, Weber B. High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen. Intervirology 2000; 43:71-76.
98. Hino K, Katoh Y, Vardas E, Sim J, Okita K, Carman WF. The effect of introduction of universal childhood hepatitis B immunization in South Africa on the prevalence of serologically negative hepatitis B virus infection and the selection of immune escape variants. Vaccine 2001; 19:3912-3918.